199 SUMMARY REFERENCES 1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. 2. van den Dries CJ, van Doorn S, Rutten FH, Oudega R, van de Leur SJCM, Elvan A, et al. Integrated management of atrial fibrillation in primary care: Results of the ALL-IN cluster randomized trial. Eur Heart J. 2020;41(30):2836–44. 3. La Roi-Teeuw HM, Van Smeden M, Bos M, De Wilde SM, Yang B, Rutten FH, et al. Estimated causal effects of common respiratory infections on cardiovascular risk: A meta-analysis. Open Heart. 2023;10(2):e002501. 4. Peltzer B, Manocha KK, Ying X, Kirzner J, Ip JE, Thomas G, et al. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19. J Cardiovasc Electrophysiol. 2020;31(12):3077–85. 5. Mountantonakis SE, Saleh M, Fishbein J, Gandomi A, Lesser M, Chelico J, et al. Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm. 2021;18(4):501–7. 6. Bhatla A, Mayer MM, Adusumalli S, Hyman MC, Oh E, Tierney A, et al. COVID-19 and cardiac arrhythmias. Heart Rhythm. 2020;17(9):1439–44. 7. Offerhaus JA, Joosten LPT, van Smeden M, Linschoten M, Bleijendaal H, Tieleman R, et al. Sex- and age specific association of new-onset atrial fibrillation with in-hospital mortality in hospitalised COVID-19 patients. IJC Heart and Vasculature. 2022;39:100970. 8. Joosten LPT, van Doorn S, Rutten FH, Geersing GJ. Stroke rate variation and anticoagulation benefit in atrial fibrillation. Annals of Internal Medicine. 2019;170:816–7. 9. Shah SJ, Eckman MH, Aspberg S, Go AS, Singer DE. Effect of variation in published stroke rates on the net clinical benefit of anticoagulation for atrial fibrillation. Ann Intern Med. 2018;169(8):517–27. 10. van Doorn S, Debray TPA, Kaasenbrood F, Hoes AW, Rutten FH, Moons KGM, et al. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: A systematic review and meta-analysis. J Thromb Haemost. 2017;15(6):1065–77. 11. Joosten LPT, de Boer AR, van Eerde EJB, van Doorn S, Hoes AW, Bots ML, et al. Atrial fibrillation: Trends in prevalence and antithrombotic prescriptions in the community. Netherlands Heart Journal. 2022;30(10):459–65. 12. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. 13. Centraal Bureau voor de Statistiek. Bevolking op 1 januari en gemiddeld; geslacht, leeftijd en regio. [Internet]. 2023 [cited 2024 Feb 17]. Available from: https://www.cbs.nl/nl-nl/ cijfers/detail/03759ned?dl=39E0B 14. Vektis. Factsheet kwetsbare ouderen. [Internet]. 2020 [cited 2024 Feb 17]. Available from: https://www.vektis.nl/intelligence/publicaties/factsheet-kwetsbareouderen#:~:text=17%25%20van%20alle%20thuiswonende%2065,%25)%20van%20 alle%20thuiswonende%20ouderen. 15. Wilkinson C, Todd O, Clegg A, Gale CP, Hall M. Management of atrial fibrillation for older people with frailty: A systematic review and meta-analysis. Age and Ageing. 2019;45:196– 204. A
RkJQdWJsaXNoZXIy MTk4NDMw